World Drug Delivery and Formulation 2010

26-27th January 2010, Radisson BLU Scandinavia Hotel, Dusseldorf, Germany.
With increasing generic competition, challenging molecules coming through discovery and continual pressure to produce cost-effective drugs, companies are increasingly turning to formulation and delivery to secure the success of current and new drug products.

World Drug Delivery and Formulation 2010 is the event this year for both scientific and business leaders working in formulation and delivery to debate the challenges affecting them.

This multi stream delivery and formulation event will focus on both scientific and business issues. This will give everyone the perfect opportunity to attend sessions dedicated to their main area of interest, whilst networking with scientific and business peers from across the entire formulation and delivery spectrum.

Attend keynote sessions, workshops and pre-arranged one-to-one meeting sessions to examine the key issues including:

  • Small molecule formulation - enhancing solubility and bioavailability
  • Biologic formulation - improving stability and preventing aggregation
  • Drug delivery partnerships - evaluating the potential of new drug delivery technologies

You will gain invaluable knowledge over the two days by taking advantage of the sessions and numerous networking opportunities. Our one-to-one meeting model enables you to choose from leading experts and solution providers in drug formulation and delivery that you want to meet, ensuring you gain the knowledge you need to improve your activities back on site.

For further information and registration, please visit:
http://www.ddfevent.com

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...